Published in Volume
100, Issue 2 (July 15, 1997)
J Clin Invest. 1997;100(2):290–295.
doi:10.1172/JCI119534.
Copyright ©
1997, The American Society for
Clinical Investigation.
Research Article
Role of nitric oxide in obesity-induced beta cell disease.
M Shimabukuro, M Ohneda, Y Lee and R H Unger
Center for Diabetes Research and Gifford Laboratories, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.
Published July 15, 1997
Here we report that free fatty acid-induced suppression of insulin output in prediabetic Zucker diabetic fatty (ZDF) rats is mediated by NO. When normal islets were cultured in 2 mM FFA, NO production and basal insulin secretion increased slightly. In cultured prediabetic ZDF islets, FFA induced a fourfold greater rise in NO, upregulated mRNA of inducible nitric oxide synthase (iNOS), and reduced insulin output; both nicotinamide and aminoguanidine, which lower NO, prevented the FFA-mediated increase in iNOS mRNA, reduced NO, and minimized the loss of insulin secretion. In vivo nicotinamide or aminoguanidine treatment of prediabetic ZDF rats prevented the iNOS expression in islets and decreased beta cell dysfunction while blocking beta cell destruction and hyperglycemia. We conclude that NO-lowering agents prevent adipogenic diabetes in obese rats.